
.png)
Event Schedule *Schedule can be subject to change |
Thursday, September 24
Time | Session |
7:30am - 8:15am 8:15am - 8:30am | Breakfast Conference Welcome |
8:30am - 9:30am | Keynote
Philomena Kebec, J.D. Chief Judge Sokaogon Chippewa Tribal Court Philomena Kebec, J.D., an enrolled member of the Bad River Band of Lake Superior Chippewa currently serves as the Chief Judge of the Sokaogon Chippewa Community Tribal Court and an attorney at Osterby Law Office, LLC, where she represents public-defender eligible litigants in state criminal cases and civil clients in tribal courts. Philomena teaches Federal Indian Law at the University of Minnesota Duluth Masters in Tribal Government and Administration Program and is a DrPH student and Bloomberg American Health Initiative Fellow at Johns Hopkins School of Public Health. Along with Aurora Conley, she founded Gwayakobimaadiziwin Bad River Harm Reduction in 2015. |
9:30am - 10:00am | Morning break and view exhibitors |
10:00am - 11:00am | Breakout Session 1.1 Buprenorphine Beyond the Clinic: Expanding Addiction Care Through Street Medicine Elizabeth Lownik, MD, MPH, FAAFP; Sarah Brown; Michael Fitzpatrick; Emily Reimer Opioid-related deaths are overrepresented amongst communities without stable housing; however, access to lifesaving buprenorphine treatment is often limited in this population. Integrating buprenorphine treatment in non-traditional settings has been identified as a recommendation to reduce barriers to buprenorphine treatment amongst people experiencing homelessness. To improve access, the St. Clare Health Mission in partnership with the Gundersen Family Medicine Department in La Crosse, Wi implemented an addiction medicine component to their weekly Rotary Mobil Clinic street medicine outreach. Within the first 12 months of operation, the team was able to obtain and distribute >400 doses of naloxone, offer point of care fentanyl testing, and support 45 addiction-related street medicine encounters and 15 buprenorphine initiations with successful follow up. Additional support is facilitated for patients who are interested and able to access it through local community resources, with the goal of transitioning people to more stable housing and care. In this presentation, we will describe the development of this low-barrier buprenorphine outreach program, including the lessons we have learned, challenges with implementation, and early program outcomes. We will then take time to facilitate a group discussion on opportunities to adapt and expand similar outreach-based addiction care models across diverse Wisconsin communities. |
10:00am - 11:00am
| Breakout Session 1.2 Integrating Peer Recovery into Outpatient Care: Lessons from Implementation, Lived Experience, and Collaboration Christina Mundschau MS, SAC-IT, CRPS; Page Feller This interactive session explores real-world learnings from the implementation of peer recovery support services within Rogers Behavioral Health’s outpatient grant-funded programs, including WORTH IT and Women’s services. Grounded in lived experience, evidence-based practices, and resilience-oriented care, presenters will share practical insights on how peer support roles can be effectively integrated into multidisciplinary treatment teams while maintaining their unique value. Rather than focusing solely on theory, this session prioritizes lessons learned—including wins, challenges, boundary considerations, and evolving role clarity—drawn directly from program implementation. Participants will explore how peer recovery specialists differ from, overlap with, and complement roles such as therapists and case managers; how peers navigate the intersection of personal and professional experience; and how peer support enhances engagement, retention, and recovery outcomes—particularly for underserved and marginalized populations. The session will include brief educational framing, program data highlights, case examples, and facilitated discussion to encourage shared learning and collaboration across systems. |
11:00am - 11:15am | Morning Mini-Beak |
11:15am - 12:15pm | Breakout Session 2.1 Responding to Risk of Arrest and Incarceration in Perinatal Substance Use Disorder Elise Wessol, DO; Ruchi Fitzgerald, MD, FAAFP, FASAM; Cayse Powell, MD, MPH; Sammi Shay, LCSW, PMH-C; Lexi Gonzalez This capacity-building workshop equips clinicians with practical skills to meet the moment of rising rates of criminal legal system involvement among pregnant and postpartum people with substance use disorders (SUD), a trend associated with disrupted care, worsening maternal and neonatal outcomes, and increased barriers to evidence-based treatment. Importantly, legal system involvement is often driven less by substance use severity itself and more by social determinants of health, systemic bias, mandated reporting practices, and lack of access to supportive services. Evidence consistently demonstrates that punitive approaches are associated with worse maternal and neonatal outcomes, decreased prenatal care engagement, and increased overdose risk. |
11:15am - 12:15pm | Breakout Session 2.2 Ketamine the Chameleon: Exploring Applications and Uses Across Clinical Settings Chantelle Thomas, PhD Medication diversion—the use of prescribed medication by someone other than the intended patient—is a recognized challenge in Medication for Opioid Use Disorder (MOUD) programs. It cannot be completely prevented and is difficult to measure, yet its consequences can be substantial: increased overdose risk among opioid-naïve individuals, stigma around MOUD as a legitimate treatment, and heightened scrutiny from law enforcement and regulators, including the DEA. Despite these concerns, critical questions remain: How dangerous is diversion? How often does it occur? This session will review the available literature to address both. We will then outline the components of a comprehensive Diversion Control Plan (DCP), providing a framework for understanding how programs can systematically approach diversion prevention while balancing patient care. A central focus is medication call backs (MCBs)—procedures requiring patients to present remaining medication within a specified timeframe. We examine the challenges, benefits, and harms of MCBs, drawing on data from a system of over 60 Opioid Treatment Programs with more than 35,000 MCBs from 2019–2025, including how frequently MCBs are conducted, the proportion of patients who pass or fail, and the impact of failed MCBs on patient retention. |
12:15pm - 1:15pm 1:15pm - 1:30pm | Lunch View exhibits and transition to afternoon breakouts |
1:30pm - 2:00pm | Breakout Session 3.1 A Family Affair: Practical Strategies for Treating Both Parents and Adolescents Molly Perri, MD; Danielle Rodriguez; Nicole Gastala; Arushi Joshi Substance use affects entire families, yet parents and adolescents are often treated in isolation. Through the evolving case of a 17-year-old with opioid use disorder and his mother, this interactive workshop will examine substance use from both the parent and child perspectives. Participants will explore how stigma, trauma, family separation, housing instability, and barriers to care shape treatment engagement and recovery. The session will provide practical guidance on trauma-informed and harm-reduction care, thoughtful interpretation of urine drug screening, comprehensive adolescent assessment, developmentally appropriate motivational interviewing, and legal considerations related to minor consent and confidentiality. Ultimately, the workshop will challenge attendees to imagine a more integrated, family-centered model of substance use care. |
1:30pm - 2:30pm | Breakout Session 3.2 Who, What, Where, When, Why, and How: Leveraging Overdose Data to Action Caitlin Murphy, PhD An overview of current overdose trends and emerging data in Wisconsin will be provided, including key patterns and recent developments shaping prevention and response efforts. Participants will then engage in a practical, step-by-step guide focused on turning data into action and will learn how to use information strategically to inform programs, practice, partnerships, policies, and community response. |
2:30pm - 3:00pm | Afternoon Break and exhibit viewing |
3:00pm - 4:00pm | Breakout Session 4.1 Solution-Focused Brief Therapy for Perinatal Substance Use: Clinical Applications Workshop Matthew Stohs, MD; Sarah Trost, PhD; McKenzie Paige, MD, MS Discover valuable resources from SFBT to equip patients with substances use disorders in a peripartum setting. |
3:00pm - 4:00pm | Breakout Session 4.2 Safer Smoking: Emerging Risks, Harm Reduction Strategies, and Clinical Applications in Wisconsin and Beyond Elizabeth Salisbury-Afshar, MD, MPH; Jake Niesen |
4:00pm - 4:15pm | Break and transition to keynote |
4:15pm - 5:15pm | Keynote
Michael Elkin, LMFT Michael Elkin, LMFT, Internal Family Systems Michael Elkin has been struggling with addiction for over fifty years. After a brief adventure with heroin while still in high school in the 1950's, he found that his experiences as a marginal jazz musician qualified him to practice psychotherapy with people colonized by drugs. Initially his only resources in this project were the skills he acquired as a minor league pool and poker hustler, but he was fortunate to find mentors who taught him to add strategic and structural family therapy and hypnosis to his repertoire. In 1984 he published Families Under the Influence (Norton, still in print) and began teaching systemic approaches to addiction throughout the US and Europe. In 1995 he discovered Richard Schwartz's Internal Family Systems therapy model, which he considers to be the most effective tool for healing currently available. He is dedicated to helping healers use this model effectively. |
5:15pm - 7:00pm | Artwork Reception and Social |
7:30am - 6:00pm | Exhibit Hall Open |
Friday, September 25 |
Time | Session |
7:30am - 8:30am 8:30am - 8:45am | Breakfast Conference Welcome |
Keynote
Dr. Stephen Delisi, MD, CMO, Faculty, Co-Director Hazelden Betty Ford, YourPath, UC-Irvine TNT-PC-Team Dr. Delisi is board certified by both the American Board of Psychiatry and Neurology and the American Board of Addiction Medicine. He currently serves as the Chief Medical Officer for YourPath and President of YourPath Care, PLLC. He is also the Co-Associate Director for the UC-Irvine School of Medicine Train New Trainers (TNT) Primary Care – Training and Education in Addiction Medicine (PC-TEAM) Fellowship. Dr. Delisi is also a long-term board member and Medical Director for the non-profit Steve Rummler Hope Network. Before joining the YourPath team as CMO and President, Dr. Delisi had served as a psychiatrist for the Hazelden Betty Ford Foundation from 2005-2023. During his time with Hazelden, Dr. Delisi most recently served as Medical Director, Enterprise Solutions and Medical Education Services. Prior to that role, he was Medical Director of Professional Education, Training & Consultation, Assistant Dean of the Hazelden Betty Ford Graduate School, and Midwest Regional Medical Director for Recovery Services at Hazelden Betty Ford. Dr. Delisi continues as an Adjunct Professor at the Hazelden Betty Ford Graduate School and as an On-call Medical Trainer. Prior to joining Hazelden Betty Ford, he held positions as Director of Psychiatric Services at Rush Behavioral Health-DuPage and Associate Director of the Psychiatric Residency Program at Rush University Medical Center. Dr. Delisi is a nationally recognized leader, speaker, and consultant on the use of evidence-based, integrated treatments for co-occurring and substance use disorders, as well as the risk conferred by the epigenetic effects of Adverse Childhood Experiences and trauma. |
9:45am - 10:00am 10:00am - 11:00am | Morning Break Breakout Session 5.1 - Poster Symposium |
10:00am - 11:00am | Breakout Session 5.2 Medication Call Backs in MOUD: Balancing Diversion Control and Patient-Centered Care Hillary Tamar, MD Medication diversion—the use of prescribed medication by someone other than the intended patient—is a recognized challenge in Medication for Opioid Use Disorder (MOUD) programs. It cannot be completely prevented and is difficult to measure, yet its consequences can be substantial: increased overdose risk among opioid-naïve individuals, stigma around MOUD as a legitimate treatment, and heightened scrutiny from law enforcement and regulators, including the DEA. Despite these concerns, critical questions remain: How dangerous is diversion? How often does it occur? This session will review the available literature to address both. We will then outline the components of a comprehensive Diversion Control Plan (DCP), providing a framework for understanding how programs can systematically approach diversion prevention while balancing patient care. A central focus is medication call backs (MCBs)—procedures requiring patients to present remaining medication within a specified timeframe. We examine the challenges, benefits, and harms of MCBs, drawing on data from a system of over 60 Opioid Treatment Programs with more than 35,000 MCBs from 2019–2025, including how frequently MCBs are conducted, the proportion of patients who pass or fail, and the impact of failed MCBs on patient retention. |
11:00am - 11:15am 11:15am - 12:15pm 12:15pm -1:15pm 1:15pm - 1:30pm | Break and transition Poster Session Lunch and Annual Meeting Transition |
1:30pm - 2:30pm | Breakout Session 6.1 Undoing Stigma: Meaningfully Engaging People Who Use Drugs in Research & Practice Abby Delkamp, BS In today’s world, people who use drugs (PWUD) often face significant stigma and are frequently excluded from decision-making in the development of research and services that affect their health. Yet, research shows that involving PWUD in these processes can greatly improve the relevance and impact of research and services. In this session, we will explore stigma, the impacts of stigma, and how we can undo stigma by adopting harm reduction approaches and including PWUD in substance use research and practice. Through a data-driven lens, we’ll look at the prevalence of stigma among PWUD in WI and how it can affect a person’s ability to access services they need. This session emphasizes the value of incorporating lived experience in research and practice. Participants will learn tools needed to meaningfully engage and elevate the voices of PWUD in all stages of the research and program improvement process. Participants will have the opportunity to apply these practical tools through an interactive activity focused on designing inclusive and respectful research and program improvement approaches. |
1:30pm - 2:30pm | Breakout Session 6.2 Advancing Equitable Injectable PrEP Access for People Using Drugs and Chemsex Communities Cayse Powell, Ruchi Fitzgerald, MD, FAAFP, FASAM; Francesco Tani, DO, FASAM, AAHIVS This session will review the pharmacology, efficacy, safety, and implementation of CAB-LA and LEN within addiction medicine, harm reduction, LGBTQ+ health, and community-based care models. Faculty will discuss practical approaches to integrating injectable PrEP into low-threshold settings, addressing insurance and operational barriers, and providing trauma-informed, culturally responsive HIV prevention services for people who use drugs and individuals engaged in chemsex. Through concise didactic updates, case-based discussion, and interactive audience participation, faculty will guide participants through the key components of long-acting injectable PrEP delivery, including pharmacology, patient selection, operational workflows, insurance navigation, sexual health integration, and culturally responsive implementation strategies. |
2:30pm - 2:45pm | Afternoon Mini-Break |
2:45pm - 3:45pm | Breakout Session 7.1 Seeking Stability in OUD Care: Person-Centered Transitions from Methadone to Buprenorphine Ezra Lyon, MD, FASAM; Ian Latham This interactive workshop will teach participants how to help patients transition smoothly from methadone to buprenorphine and from OTP to OBOT. Participants will learn pharmacologic strategies for transition including low-dose initiation of buprenorphine with continuation of methadone. The workshop will be a mixed of didactic material and case-based small group learning. |
2:45pm - 3:45pm | Breakout Session 7.2 Beyond Weight Loss: The Emerging Role of GLP-1 Receptor Agonists in Addiction Todd Stollenwerk, MD, PhD; Selahattin Kurter; Vani Ray, MD, DFAPA, FACLP, FASAM Evidence for GLP-1 receptor agonists in the treatment of patients with addiction, including alcohol use disorder, opioid use disorder, stimulant use disorder, and tobacco use disorder. |
3:45pm - 4:00pm | Closing Comments |